In contrast, another study has shown that VEGFR2 expression and its downstream Ras/MEK/ERK signaling are elevated in lenvatinib-resistant HCC cells, with no changes in VEGFR1, VEGFR3, FGFR1-4, and PDGFRα/β expression [222]. This evidence concerns the gene MAP2K7 and hepatocellular carcinoma.